Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony W Tolcher

Showing results (1-10 of 123) with videos related to

Pageof 13
Sort By:
Chinese Journal of Cancer|November 9, 2011
The evolution of phase I trials in cancer medicine: a critical review of the last decadeAnthony W Tolcher
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 1, 2020
The Evolution of Antibody-Drug Conjugates: A Positive Inflexion PointAnthony W Tolcher
The Journal of Urology|January 10, 2004
Novel therapeutic molecular targets for prostate cancer: the mTOR signaling pathway and epidermal growth factor receptorAnthony W Tolcher
Hematology/Oncology Clinics of North America|January 7, 2003
Regulators of apoptosis as anticancer targetsAnthony W Tolcher
Cancer Journal (Sudbury, Mass.)|October 15, 2009
Stable disease is a valid end point in clinical trialsAnthony W Tolcher
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotidesAnthony W Tolcher
Pharmacology & Therapeutics|June 23, 2022
Antibody drug conjugates: The dos and don'ts in clinical developmentAnthony W Tolcher
Current Opinion in Investigational Drugs (London, England : 2000)|July 10, 2004
Development of novel alkylating drugs as anticancer agentsElzbieta Izbicka, Anthony W Tolcher
Current Oncology Reports|June 26, 2007
The role of mTOR inhibitors for treatment of sarcomasMonica M Mita, Anthony W Tolcher
Nature Clinical Practice. Oncology|March 30, 2007
Technology insight: cytotoxic drug immunoconjugates for cancer therapyAlejandro D Ricart, Anthony W Tolcher
Pageof 13

Showing results (1-10 of 123) with videos related to

Sort By:
Pageof 13
Chinese Journal of Cancer|November 9, 2011
The evolution of phase I trials in cancer medicine: a critical review of the last decadeAnthony W Tolcher
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 1, 2020
The Evolution of Antibody-Drug Conjugates: A Positive Inflexion PointAnthony W Tolcher
The Journal of Urology|January 10, 2004
Novel therapeutic molecular targets for prostate cancer: the mTOR signaling pathway and epidermal growth factor receptorAnthony W Tolcher
Hematology/Oncology Clinics of North America|January 7, 2003
Regulators of apoptosis as anticancer targetsAnthony W Tolcher
Cancer Journal (Sudbury, Mass.)|October 15, 2009
Stable disease is a valid end point in clinical trialsAnthony W Tolcher
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotidesAnthony W Tolcher
Pharmacology & Therapeutics|June 23, 2022
Antibody drug conjugates: The dos and don'ts in clinical developmentAnthony W Tolcher
Current Opinion in Investigational Drugs (London, England : 2000)|July 10, 2004
Development of novel alkylating drugs as anticancer agentsElzbieta Izbicka, Anthony W Tolcher
Current Oncology Reports|June 26, 2007
The role of mTOR inhibitors for treatment of sarcomasMonica M Mita, Anthony W Tolcher
Nature Clinical Practice. Oncology|March 30, 2007
Technology insight: cytotoxic drug immunoconjugates for cancer therapyAlejandro D Ricart, Anthony W Tolcher
Pageof 13